Prelude Therapeutics (PRLD) Current Leases (2019 - 2026)

Prelude Therapeutics has disclosed Current Leases across 7 years of filings, most recently posting $2.8 million for Q1 2026.

• Current Leases for Q1 2026 came in at $2.8 million, up 6.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.8 million (up 6.19% YoY), and the FY2025 annual result was $2.7 million, up 10.11% from the prior year.
• Current Leases came in at $2.8 million for Q1 2026 at Prelude Therapeutics, up from $2.7 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $2.8 million in Q1 2026 to a low of $475000.0 in Q3 2023.
• The 5-year median for Current Leases is $2.2 million (2024), against an average of $2.0 million.
• Across the five-year window, Current Leases tumbled 65.78% in 2023 and jumped 397.89% in 2024, its largest moves.
• Prelude Therapeutics' Current Leases stood at $1.8 million in 2022, then retreated by 19.16% to $1.5 million in 2023, then surged by 68.26% to $2.5 million in 2024, then grew by 10.11% to $2.7 million in 2025, then gained by 0.62% to $2.8 million in 2026.
• The last three Current Leases figures came in at $2.8 million (Q1 2026), $2.7 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.